A real-world disproportionality analysis of Tivozanib data mining of the public version of FDA adverse event reporting system
BackgroundTivozanib, a vascular endothelial growth factor tyrosine kinase inhibitor, has demonstrated efficacy in a phase III clinical trials for the treatment of renal cell carcinoma. However, comprehensive evaluation of its long-term safety profile in a large sample population remains elusive. The...
I tiakina i:
| Ngā kaituhi matua: | , , , |
|---|---|
| Hōputu: | Pukapuka |
| I whakaputaina: |
Frontiers Media S.A.,
2024-06-01T00:00:00Z.
|
| Ngā marau: | |
| Urunga tuihono: | Connect to this object online. |
| Ngā Tūtohu: |
Tāpirihia he Tūtohu
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!
|
Ipurangi
Connect to this object online.3rd Floor Main Library
| Tau karanga: |
A1234.567 |
|---|---|
| Tārua 1 | Wātea |